Novaliq
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Novaliq sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Novaliq: 7 sponsored US clinical trials, 1 recruiting.
Novaliq sponsors 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 6 completed. 3 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dry Eye Syndromes, with 1 trials.
Upper-quartile sponsor footprint
Novaliq sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis
NCT07285070
A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine
NCT06329661
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004
NCT04523142
ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
NCT04523129
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
NCT03333057
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
NCT03292809
CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)
NCT02617667
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Novaliq pipeline
1 recruiting of 7 indexed (14% open); 6 completed (86%).
Phase mix: 3 late (III/IV) vs 4 early (I/II) (balanced across stages).
Top condition: Dry Eye Syndromes (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Novaliq: open-pipeline peers nationwide
Peers matched on 7 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Novaliq sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this Novaliq page
7 registered trials is a research-attention snapshot, not an endorsement of Novaliq or any single study.
- 1 of Novaliq's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Dry Eye Syndromes is the condition Novaliq studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dry Eye Syndromes trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Novaliq pipeline card: 7 registered trials from official public datasets.Report a data error.